Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1

Hideki Iijima1, Markus F Neurath, Takashi Nagaishi

  • 1Gastroenterology Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Insights

Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) regulates T helper 1 (Th1) cell responses. Targeting CEACAM1 reduces Th1-mediated inflammation, offering potential therapeutic strategies for inflammatory bowel disease.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) is a cell surface molecule implicated in T cell regulation.
  • CEACAM1's specific role in T helper cell (Th)1 pathways and associated immunopathology requires further elucidation.

Purpose of the Study:

  • To investigate the function of CEACAM1 in regulating Th1-mediated inflammation in vivo and in vitro.
  • To determine the therapeutic potential of targeting CEACAM1 in models of inflammatory bowel disease.

Main Methods:

  • Treatment of mice with anti-CEACAM1 monoclonal antibody (mAb) CC1 or CEACAM1-Fc chimeric protein in trinitrobenzene sulfonic acid and oxazolone colitis models.
  • Analysis of cytokine production (e.g., interferon-gamma) and transcription factor activation (e.g., T-bet).
  • In vitro studies involving T cell ligation with murine hepatitis virus spike protein.

Main Results:

  • Anti-CEACAM1 treatment reduced colitis severity and decreased interferon-gamma production in both models.
  • CEACAM1 blockade significantly reduced T-bet activation without affecting signal transducer and activator of transcription 4.
  • In vitro, CEACAM1 ligation inhibited Th1 differentiation and cytokine production but not Th2 responses.

Conclusions:

  • CEACAM1 isoforms are novel, activation-induced cell surface molecules on T cells.
  • CEACAM1 specifically regulates Th1-mediated inflammation, including inflammatory bowel disease.
  • Targeting CEACAM1 presents a potential therapeutic strategy for Th1-driven inflammatory conditions.